TY - JOUR
T1 - Comparison of complementary diagnostic tests in cerebrospinal fluid and serum for neurocysticercosis
AU - Romo, Matthew L.
AU - Carpio, Arturo
AU - Parkhouse, R. Michael E.
AU - Cortéz, María Milagros
AU - Rodríguez-Hidalgo, Richar
N1 - Publisher Copyright:
© 2018 The Authors
PY - 2018/12
Y1 - 2018/12
N2 - The role of immunologic tests in the diagnosis of neurocysticercosis (NC) is controversial and few studies have made comparisons among them. The objective of this study was to compare immunological tests in both serum and cerebrospinal fluid (CSF) for the diagnosis of NC. We conducted a case-control study in Cuenca, Ecuador, enrolling patients with NC (N = 24) and matching them with other neurosurgical patients (N = 18). To detect cysticercal antigen, we used an HP10 antigen assay in serum and CSF (“HP10 Ag -serum -CSF”) and a commercial antigen assay in serum (apDia, “ELISA-Ag-serum”), and to detect cysticercal DNA, we used a polymerase chain reaction (PCR) assay in CSF (“PCR-CSF”). Assay sensitivities were: HP10 Ag-serum (41.7%, 95% confidence interval [CI] 22.1–63.4), HP10 Ag-CSF (87.5%, 95% CI: 67.6–97.3), ELISA-Ag-serum (62.5%, 95% CI: 40.6–81.2), and PCR-CSF (79.2%, 95% CI: 57.9–92.9). Sensitivities were higher when limiting to participants with extraparenchymal NC. Specificity was 100% for all assays except ELISA-Ag-serum (72.2%). This preliminary study demonstrated the potential usefulness of the PCR and HP10 Ag assay in CSF, especially for extraparenchymal NC; thus, they could be considered as complementary diagnostic tools when neuroimaging is not conclusive.
AB - The role of immunologic tests in the diagnosis of neurocysticercosis (NC) is controversial and few studies have made comparisons among them. The objective of this study was to compare immunological tests in both serum and cerebrospinal fluid (CSF) for the diagnosis of NC. We conducted a case-control study in Cuenca, Ecuador, enrolling patients with NC (N = 24) and matching them with other neurosurgical patients (N = 18). To detect cysticercal antigen, we used an HP10 antigen assay in serum and CSF (“HP10 Ag -serum -CSF”) and a commercial antigen assay in serum (apDia, “ELISA-Ag-serum”), and to detect cysticercal DNA, we used a polymerase chain reaction (PCR) assay in CSF (“PCR-CSF”). Assay sensitivities were: HP10 Ag-serum (41.7%, 95% confidence interval [CI] 22.1–63.4), HP10 Ag-CSF (87.5%, 95% CI: 67.6–97.3), ELISA-Ag-serum (62.5%, 95% CI: 40.6–81.2), and PCR-CSF (79.2%, 95% CI: 57.9–92.9). Sensitivities were higher when limiting to participants with extraparenchymal NC. Specificity was 100% for all assays except ELISA-Ag-serum (72.2%). This preliminary study demonstrated the potential usefulness of the PCR and HP10 Ag assay in CSF, especially for extraparenchymal NC; thus, they could be considered as complementary diagnostic tools when neuroimaging is not conclusive.
KW - Evidence-based medicine
KW - Infectious disease
KW - Neurology
UR - https://www.scopus.com/pages/publications/85057436405
U2 - 10.1016/j.heliyon.2018.e00991
DO - 10.1016/j.heliyon.2018.e00991
M3 - Artículo
AN - SCOPUS:85057436405
SN - 2405-8440
VL - 4
JO - Heliyon
JF - Heliyon
IS - 12
M1 - e00991
ER -